Emmanuelle Ferrant
YOU?
Author Swipe
View article: 219 | PATIENT REPORTED OUTCOMES FROM BRUIN CLL‐321: PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKi PRETREATED CLL/SLL
219 | PATIENT REPORTED OUTCOMES FROM BRUIN CLL‐321: PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKi PRETREATED CLL/SLL Open
View article: Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ <i>TP53</i> Mutation: SEQUOIA Arm D Results
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ <i>TP53</i> Mutation: SEQUOIA Arm D Results Open
PURPOSE Several chronic lymphocytic leukemia (CLL) studies have demonstrated promising efficacy with the combination of BCL2 and Bruton tyrosine kinase inhibitors; however, patients with CLL with del(17p) and/or TP53 mutation ( TP53 mut) c…
View article: Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time? Open
View article: Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN Open
Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia. We present results from ELEVATE-TN after a median follow-up of 74.5 months. Overall, 535 patients were randomized (acalabrutini…
View article: Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study
Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study Open
View article: Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia Open
View article: End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy Open
Background In spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die from this disease or related complications. While a great amount of focus has been dedicated to the development of novel ther…
View article: Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial Open
Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorub…
View article: Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital Open
International audience
View article: A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial Open
In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing patients from serious toxicities. The ICLL-07 …
View article: Legionella Pneumophila Serogroup 1 Serum LPS Detection as a Biomarker for Legionnaires’ Disease Prognosis: A Multicentre Prospective Cohort Study
Legionella Pneumophila Serogroup 1 Serum LPS Detection as a Biomarker for Legionnaires’ Disease Prognosis: A Multicentre Prospective Cohort Study Open
View article: Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)
Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study) Open
International audience
View article: HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma Open
Despite their unprecedented success in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), anti-CD19 CAR T cells are associated with significant toxicity, and more than half of patients relapse. As monocytes emerged as key players in C…
View article: <scp>TP53</scp> mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia
<span>TP53</span> mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia Open
International audience
View article: Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients
Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients Open
View article: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia Open
Bruton tyrosine kinase (BTK) inhibitors have improved chronic lymphocytic leukemia (CLL) outcomes and offer a chemotherapyfree option [1].The BTK inhibitor ibrutinib, alone or with a CD20 antibody, demonstrated better efficacy versus chemo…
View article: Crystal‐storing histiocytosis and Bing‐Neel‐like syndrome revealing a small B‐cell lymphoma with plasmacytic differentiation, presumed to be a marginal zone lymphoma
Crystal‐storing histiocytosis and Bing‐Neel‐like syndrome revealing a small B‐cell lymphoma with plasmacytic differentiation, presumed to be a marginal zone lymphoma Open
Crystal‐storing histiocytosis and Bing‐Neel syndrome are two diseases induced by paraproteins. Herein, we report a rare case of crystal‐storing histiocytosis associated with Bing‐Neel‐like neurological manifestations in the context of a sm…
View article: Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified Open
In this retrospective study, we report 70 cases of Epstein-Barr virus (EBV)+ diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) among 1696 DLBCL-NOS cases diagnosed between 2006 and 2019 (prevalence of 4.1%). At diagnosis, m…
View article: Crystal Storing Histiocytosis and Bing-Neel-like syndrome revealing a marginal zone lymphoma with plasmacytic differentiation.
Crystal Storing Histiocytosis and Bing-Neel-like syndrome revealing a marginal zone lymphoma with plasmacytic differentiation. Open
Crystal Storing Histiocytosis and Bing Neel Syndrome are two diseases induced by paraprotein. Herein, we report a rare case of Crystal Storing Histiocytosis associated with Bing-Neel-like neurological manifestations in the context of margi…
View article: Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia Open
View article: Commercial <scp>anti‐CD19 CAR</scp> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
Commercial <span>anti‐CD19 CAR</span> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center Open
Two autologous anti‐CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). …
View article: L’émergence des traitements par cellules CAR-T dans les lymphomes
L’émergence des traitements par cellules CAR-T dans les lymphomes Open
View article: Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study Open
International audience
View article: Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib Open
Key Points Ibrutinib may be associated with invasive fungal infections especially IA. Most infections usually occur during the first months of treatment, often in patients with other risk factors for fungal infections.
View article: Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups Open
View article: Emergency and elective pulmonary surgical resection in haematological patients with invasive fungal infections: a report of 50 cases in a single centre
Emergency and elective pulmonary surgical resection in haematological patients with invasive fungal infections: a report of 50 cases in a single centre Open
View article: Evaluating the Role and Efficacy of Plerixafor in Rescue Mobilization of Autologous Peripheral Blood Stem Cells
Evaluating the Role and Efficacy of Plerixafor in Rescue Mobilization of Autologous Peripheral Blood Stem Cells Open
In autologous hematopoietic stem cell transplantation patients for whom granulocyte-colony stimulating factor fails to mobilize a sufficient number of peripheral blood stem cells, plerixafor proposes an option for successful rescue mobiliz…